Cancer stem cells as the relevant biomass for drug discovery

Current Opinion in Pharmacology

Volumn 10, Issue 4, 2010, Pages 385-390

  Winquist, Raymond J ^a   Furey, Brinley F ^a   Boucher, Diane M ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; CYCLOPAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH RECEPTOR; PACLITAXEL; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BIOMASS; CANCER CELL CULTURE; CANCER STEM CELL; CELL ASSAY; CELL DEATH; CELL ISOLATION; CELL POPULATION; DRUG CYTOTOXICITY; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE ACTIVATED CELL SORTING; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 77955278329     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.06.008     Document Type: Review

References (42)

1. Croker A.K., Allan A.L. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008, 12:374-390.
2. Shoemaker R.H., Wolpert-Defilippes M.K., Kern D.H., Lieber M.M., Makuch R.W., Melnick N.R., Miller W.T., Salmon S.E., Simon R.M., Venditti J.M., et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985, 45:2145-2153.
3. Moon Y.W., Sohn J.H., Kim Y.T., Chang H., Jeong J.H., Lee Y.J., Chang J., Kim S.K., Jung M., Hong S., et al. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer. Anticancer Res 2009, 29:4243-4249.
4. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
5. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
6. Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146. 10.1371/journal.pone.0006146.
7. Winquist R.J., Boucher D.M., Wood M., Furey B.F. Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine. Biochem Pharmacol 2009, 78:326-334.
8. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
9. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284.
10. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemia stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:718-743.
11. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer stem cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
12. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
13. Ho M.M., Ng A.V., Lam S., Huang J.V. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67:4827-4833.
14. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
15. Collins A.T., Berry P.A., Hyde C., Stower M.J., Matland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
16. Lottaz C., Beier D., Meyer K., Kumar P., Hermann A., Schwarz J., Junker M., Oefner P.J., Bogdahn U., Wischhusen J., et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010, 70:2030-2040.
17. Wang J., Sakariassen P.O., Tsinkalovsky O., Immervoll H., Boe S.O., Svendsen A., Prestegarden L., Rosland G., Thorsen F., Stuhr L., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008, 122:761-768.
18. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., Greve J.M., Soriano R.H., Gilmour L.L., Rivers C.S., et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
19. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, R25. [Epub March 26].
20. Charafe-Jauffret E., Ginestier C., Birnbaum D. Breast cancer stem cells: tools and models to rely on. BMC Cancer 2009, [Epub June 25th].
21. Wong D.J., Liu H., Ridky T.W., Cassarion D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344.
22. Stevenson M., Mostertz W., Acharya C., Kim W., Walters K., Barry W., Higgins K., Tuchman S.A., Crawford J., Vlahovic G., et al. Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res 2009, 15:7553-7561.
23. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 5:499-507.
24. Eyler C.D., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008, 26:2839-2845.
25. Eramo A., Ricci-Vitani L., Zeuner A., Pallini R., Lotti F., Sette G., Pilozzi E., Larocca L.M., Peschle C., De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006, 13:1238-1241.
26. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
27. Hoey T., Yen W.-C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.-K., Sato A., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
28. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
29. Odoux C., Fohrer H., Hoppo T., Guzik L., Stolz D.B., Lewis D.W., Gollin S.M., Gamblin T.C., Geller G.A., Lagasse E. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008, 68:6932-6941.
30. Diamandis P., Wildenhain J., Clarke I.D., Sacher A.G., Graham J., Bellows D.S., Ling E.K., Ward R.J., Jamieson L.G., Tyers M., et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol 2007, 3:268-273.
31. Roberts P.E. Isolation and establishment of human tumor stem cells. Methods Cell Biol 2008, 86:325-342.
32. Pollard S.M., Yoshikawa K., Clarke I.D., Danovi D., Stricker S., Russell R., Bayani J., Head R., Lee M., Bernstein M., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-580.
33. Flores D.G., Ledur P.F., Abujarma A.L., Brunetto A.L., Schwartsmann G., Lenz G., Roesler R. Cancer stem cells and the biology of brain tumors. Curr Stem Cell Res Ther 2009, 4:306-313.
34. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high throughput screening. Cell 2009, 138:645-659.
35. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shiplitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
36. Panchalingam K.M., Paramchuk W.J., Chiang C-YK, Shah N., Madan A., Hood L., Foltz G., Behie L.A. Bioprocessing of human glioblastoma brain cancer tissue. Tissue Eng Part A 2010, 16:1169-1177.
37. Sehl M.E., Sinsheimer J.S., Zhou H., Lange K.L. Differential destruction of stem cells: Implications for targeted cancer stem cell therapy. Cancer Res 2009, 69:9481-9489.
38. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamasson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzleri D., et al. Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukemia. Nature 2009, 458:776-779.
39. Teng Y., Wang X., Wang Y., Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 2010, 392:373-379.
40. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., Zon L.I., Armstrong S.A. The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
41. Hambardzumyan D., Squatrito M., Carbajal E., Holland E.C. Glioma formation, cancer stem cells, and Akt signaling. Stem Cell Rev 2008, 4:203-210.
42. Yilmaz O.H., Morrison S.J. The PI-3 kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells, Mol Dis 2008, 41:73-76.